U.S. markets close in 2 hours 43 minutes
  • S&P 500

    3,890.33
    +79.18 (+2.08%)
     
  • Dow 30

    31,480.22
    +547.85 (+1.77%)
     
  • Nasdaq

    13,500.09
    +307.75 (+2.33%)
     
  • Russell 2000

    2,265.33
    +64.27 (+2.92%)
     
  • Crude Oil

    60.47
    -1.03 (-1.67%)
     
  • Gold

    1,722.40
    -6.40 (-0.37%)
     
  • Silver

    26.62
    +0.18 (+0.70%)
     
  • EUR/USD

    1.2039
    -0.0048 (-0.40%)
     
  • 10-Yr Bond

    1.4500
    -0.0100 (-0.68%)
     
  • GBP/USD

    1.3910
    -0.0013 (-0.09%)
     
  • USD/JPY

    106.8150
    +0.3130 (+0.29%)
     
  • BTC-USD

    48,673.92
    +5,035.24 (+11.54%)
     
  • CMC Crypto 200

    973.16
    +44.93 (+4.84%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on Thursday, May 14, 2020, at 9:00 a.m. ET.

A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcast will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead program is being developed as a treatment for cystic fibrosis (CF) and is in a Phase 1/2 clinical trial. The Company also believes its technology is applicable to a broad range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.

Contacts for Translate Bio

Investors

Media

Teri Dahlman

Maura Gavaghan

tdahlman@translate.bio

mgavaghan@translate.bio

857-242-7792

857-242-7789